Measurement of serum Fuc-Hpt levels can distinguish NASH from non-NASH patients, and predict the presence of ballooning hepatocytes in NAFLD patients with sufficient accuracy. The gene discussed is MRS2; the disease is metabolic dysfunction-associated steatohepatitis.